REFERENCES
- Goss P. E., Ingle J. N., Martino S., Robert N J., Muss H. B., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N. Engl. J. Med. 2003; 349(19)1793–1802, [CSA]
- Bines J., Oleske D. M., Cobleigh M. A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 1996; 14(5)1718–1729, [CSA]
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351(9114)1451–1467, [CSA], [CROSSREF]
- Carmel F. Tamoxifen and endometrial cancer: tamoxifen effects on the human female genital tract. Sem Oncol. 1997; 24(Suppl. I)SI55–SI64, [CSA]
- Oktay F., Buyuk E., Davis O., Yermakova I., Veeck L., et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum. Reprod. 2003; 18(1)90–95, [CSA], [CROSSREF]
- Helgason S., Wilking N., Carlstrom K., Damber M. G., von Schoultz B. A comparative study of the estrogenic effects of tamoxifen and 17β -estradiol in postmenopausal women. J. Clin. Endocrinol. Metab. 1982; 54(2)404–408, [CSA]
- Shiau A. K., Barstad P M., Loria P. M., Cheng L., Kushner P. J., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95(7)927–937, [CSA], [CROSSREF]
- Albain K., Barlow W., O'Malley F., Siziopikou K., Yeh I-T., et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res. Treat. 2004; 88(Suppl. 1), Abst. 37[CSA]
- Adam H. K., Patterson J. S., Kemp J V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat. Rep. 1980; 64(6–7)761–764, [CSA]
- Mitwally M. F., Casper R. F. Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril. 2001; 75(2)305–309, [CSA], [CROSSREF]
- Healey S., Tan S. L., Tulandi T., Biljan M. M. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil. Steril. 2003; 80(6)1325–1329, [CSA], [CROSSREF]
- Saphner T., Tormey D. C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 1996; 14(10)2738–2746, [CSA]
- Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. J. Natl. Cancer Inst. 2001; 93(9)684–690, [CSA], [CROSSREF]
- Jonat W., Howell A., Blomqvist C., Eiermann W., Winblad G., et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 1996; 32A(3)404–412, [CSA], [CROSSREF]
- Gershanovich M., Chaudri H. A., Campos H., Lurie H., Bonaventura A., et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol. 1998; 9(6)639–645, [CSA], [CROSSREF]
- Kaufmann M., Bajetta E., Dirix L. Y., Fein L. E., Jones S. E., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J. Clin. Oncol. 2000; 18(7)1399–1411, [CSA]
- Boccardo F., Rubagotti A., Amoroso D., Mesiti M., Massobrio M., et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res. Treat. 2003; 82(Suppl. 1)S6, Abst. 3[CSA]
- Coombes R. C., Hall E., Gibson L. J., Paridaens R., Jassem J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004; 350(11)1081–1092, [CSA], [CROSSREF]
- Jakesz R., Kaufmann M., Gnant M., Jonat W., Mittlboeck M., et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after two years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res. Treat. 2004; 88(Suppl. 1)S7, Abst. 2[CSA]